Oppenheimer & Co. Inc. Purchases 3,883 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Oppenheimer & Co. Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 290,226 shares of the biopharmaceutical company's stock after acquiring an additional 3,883 shares during the quarter. Gilead Sciences comprises 0.5% of Oppenheimer & Co. Inc.'s portfolio, making the stock its 29th largest position. Oppenheimer & Co. Inc.'s holdings in Gilead Sciences were worth $32,520,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Norges Bank bought a new position in Gilead Sciences during the 4th quarter worth approximately $1,789,254,000. FMR LLC increased its stake in Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. GAMMA Investing LLC raised its holdings in Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after purchasing an additional 2,532,070 shares during the period. Northern Trust Corp boosted its position in shares of Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $207,340,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. The trade was a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock worth $5,236,245 in the last ninety days. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Up 1.6%

GILD stock traded up $1.69 during mid-day trading on Thursday, reaching $107.62. The company had a trading volume of 6,310,720 shares, compared to its average volume of 7,640,302. The company has a market capitalization of $133.87 billion, a price-to-earnings ratio of 22.66, a PEG ratio of 0.69 and a beta of 0.29. Gilead Sciences, Inc. has a 52 week low of $66.01 and a 52 week high of $119.96. The stock has a 50 day simple moving average of $106.27 and a two-hundred day simple moving average of $103.15. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.32) EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Bank of America raised their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Cantor Fitzgerald started coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Finally, Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.